The Anticancer Potential of Doxycycline and Minocycline-A Comparative Study on Amelanotic Melanoma Cell Lines

Malignant melanoma is still a serious medical problem. Relatively high mortality, a still-growing number of newly diagnosed cases, and insufficiently effective methods of therapy necessitate melanoma research. Tetracyclines are compounds with pleiotropic pharmacological properties. Previously published studies on melanotic melanoma cells ascertained that minocycline and doxycycline exerted an anti-melanoma effect. The purpose of the study was to assess the anti-melanoma potential and mechanisms of action of minocycline and doxycycline using A375 and C32 human amelanotic melanoma cell lines. The obtained results indicate that the tested drugs inhibited proliferation, decreased cell viability, and induced apoptosis in amelanotic melanoma cells. The treatment caused changes in the cell cycle profile and decreased the intracellular level of reduced thiols and mitochondrial membrane potential. The exposure of A375 and C32 cells to minocycline and doxycycline triggered the release of cytochrome c and activated initiator and effector caspases. The anti-melanoma effect of analyzed drugs appeared to be related to the up-regulation of ERK1/2 and MITF. Moreover, it was noticed that minocycline and doxycycline increased the level of LC3A/B, an autophagy marker, in A375 cells. In summary, the study showed the pleiotropic anti-cancer action of minocycline and doxycycline against amelanotic melanoma cells. Considering all results, it could be concluded that doxycycline was a more potent drug than minocycline.

Medienart:

E-Artikel

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

Zur Gesamtaufnahme - volume:23

Enthalten in:

International journal of molecular sciences - 23(2022), 2 vom: 13. Jan.

Sprache:

Englisch

Beteiligte Personen:

Rok, Jakub [VerfasserIn]
Rzepka, Zuzanna [VerfasserIn]
Kowalska, Justyna [VerfasserIn]
Banach, Klaudia [VerfasserIn]
Beberok, Artur [VerfasserIn]
Wrześniok, Dorota [VerfasserIn]

Links:

Volltext

Themen:

Antineoplastic Agents
Apoptosis
Biomarkers, Tumor
Caspases
Cell cycle
Doxycycline
EC 3.4.22.-
ERK1/2
FYY3R43WGO
Journal Article
LC3A/B
MITF
Melanoma
Minocycline
N12000U13O

Anmerkungen:

Date Completed 03.02.2022

Date Revised 03.02.2022

published: Electronic

Citation Status MEDLINE

doi:

10.3390/ijms23020831

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM335896626